GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
This will help you achieve optimum weight loss results as your program is tailored to meet your unique needs
These benefits appear to be driven by a combination of modest improvements in CV risk factors (e.g., weight loss, glycemia, blood pressure, lipids, and body weight) and direct vascular and antiinflammatory effects that stabilize plaques and reduce atherogenesis
While early bellwether trials in the GLP-1 MDL may shape outcomes for GI-related claims, this lawsuit remains distinct and may open the door for similar NAION cases in the future
Recent studies have demonstrated abundant GLP-1 receptors in human retinal tissue, suggesting potential for direct neuroprotective effects [103]
Engaging in informed discussion with your healthcare provider is essential for determining whether GLP-1 therapy is appropriate for you and, if so, which specific agent best aligns with your clinical needs and personal preferences
